<DOC>
	<DOCNO>NCT00012025</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use ICI 182780 may fight breast cancer block activity estrogen tumor cell . PURPOSE : Phase II trial study effectiveness ICI 182780 treat patient metastatic breast cancer respond previous hormone therapy .</brief_summary>
	<brief_title>ICI 182780 Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete partial objective response rate duration response woman metastatic breast cancer fail aromatase inhibitor therapy treat fulvestrant . - Determine time disease progression overall survival woman treat drug . - Determine toxicity drug woman . OUTLINE : Patients receive fulvestrant intramuscularly day 1 . Courses repeat approximately every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 5 year disease progression . After disease progression , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Progressive localregional metastatic disease Unconfirmed new progressive multiple pulmonary nodule unequivocal radiographic evidence multiple bone metastasis allow At least 1 measurable lesion At least 20 mm CT scan MRI OR least 10 mm spiral CT scan Nonmeasurable disease include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Inflammatory breast disease Abdominal mass confirm follow image technique Cystic lesion Disease progression prior thirdgeneration aromatase inhibitor ( e.g. , anastrozole , exemestane , letrozole , vorozole ) Failed 1 prior additive hormonal therapy ( e.g. , aromatase inhibitor without tamoxifen ) Disease recurrence identify 12 month since last prior adjuvant tamoxifen treatment Oophorectomy , ovarian radiotherapy , luteinizing hormonereleasing hormone ( LHRH ) analog consider hormonal therapy regimens No brain leptomeningeal metastases No hepatic metastasis involve onethird liver No symptomatic pulmonary lymphangitic disease Evidence hormone sensitivity define : Relapse least 12 month adjuvant hormonal treatment Tumor remission stabilization progression least 6 month prior hormonal therapy advance disease Postmenopausal define one following : At least 12 month since last menstrual period 411 month since last menstrual period folliclestimulating hormone ( FSH ) postmenopausal range Prior castration castrate FSH level within postmenopausal range Hysterectomy without oophorectomy ( FSH postmenopausal range age 60 ) Hormone receptor status : Estrogenreceptor and/or progesteronereceptor positive At least 10 fmol/mg cytosol protein OR Positive immunohistochemistry PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : See Disease Characteristics Postmenopausal Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 No history bleed diathesis Hepatic : See Disease Characteristics Bilirubin great 0.8 mg/dL upper limit normal ( ULN ) INR great 1.6 No hepatitis B C No severe hepatic impairment Renal : Calcium great 10 % ULN Creatinine great 1 mg/dL ULN No severe renal impairment Cardiovascular : No unstable uncompensated cardiac condition Pulmonary : No unstable uncompensated respiratory condition Other : HIV negative No AIDS No severe condition systemic disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Prior trastuzumab ( Herceptin ) allow Chemotherapy : Prior adjuvant chemotherapy allow No 1 prior chemotherapy regimen metastatic disease Endocrine therapy : See Disease Characteristics More 4 week since prior estrogen replacement therapy More 3 month since prior LHRH analogs No prior additive hormonal therapy except thirdgeneration aromatase inhibitor tamoxifen Radiotherapy : See Disease Characteristics Concurrent radiotherapy control bone pain reason due establish bone lesion allow radiotherapy field 30 % bone marrow Surgery : See Disease Characteristics Other : More 4 week since prior investigational drug breast cancer No concurrent longterm warfarin Concurrent bisphosphonates allow dose stable Concurrent longterm antiplatelet therapy allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>